SYBX - マイア―ルエヌエイ・セラピュ―ティクス (Synlogic Inc.) マイア―ルエヌエイ・セラピュ―ティクス

 SYBXのチャート


 SYBXの企業情報

symbol SYBx
会社名 Synlogic Inc (マイア―ルエヌエイ・セラピュ―ティクス)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 事業概要 Synlogic Inc. formerly Mirna Therapeutics Inc. is engaged in the development of a novel class of living treatments Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions including inflammatory bowel disease cancer and metabolic conditions such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.   マイア―ルエヌエイ・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、鎖長の短いマイクロRNAベ―スを用い抗がん剤の開発に従事する。遺伝子の発現パタ―ンの違いでがんが発生し、腫瘍を抑制するマイクロRNAはがんにより減少することを利用。通常の細胞ががん細胞に変わるのを防ぐ腫瘍抑制マイクロRNAを特定する。本社はテキサス州オ―スティン。   Synlogic™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic therapeutics that target validated underlying biology to treat disease in new ways. Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX). The company is also building a portfolio of partner-able assets in immunology and oncology.
本社所在地 301 Binney St. Suite 402 Cambridge MA 02142 USA
代表者氏名 Michael F. Powell マイケル・F・パウエル
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-401-9975
設立年月日 39417
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 63人
url www.synlogictx.com
nasdaq_url https://www.nasdaq.com/symbol/sybx
adr_tso
EBITDA EBITDA(百万ドル) -47.49700
終値(lastsale) 12.3
時価総額(marketcap) 312800660.4
時価総額 時価総額(百万ドル) 229.89580
売上高 売上高(百万ドル) 0.83000
企業価値(EV) 企業価値(EV)(百万ドル) 87.36980
当期純利益 当期純利益(百万ドル) -49.37700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Synlogic Inc revenues decreased 73% to $608K. Net loss increased 54% to $25.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 41% to $19.2M (expense) General and administrative increase of 55% to $8.4M (expense) Interest expense increase of 73% to $26K (expense).

 SYBXのテクニカル分析


 SYBXのニュース

   Synlogic (SYBX) Investor Presentation - Slideshow  2022/03/04 22:05:27 Seeking Alpha
   Synlogic appoints Michael Jensen as CFO  2022/03/03 12:36:58 Seeking Alpha
Synlogic (SYBX) has appointed Michael Jensen as CFO. Mr
   Synlogic Inc Shares Fall 0.5% Below Previous 52-Week Low - Market Mover  2022/01/14 01:12:46 Kwhen Finance
Synlogic Inc (SYBX) shares closed 0.5% lower than its previous 52 week low, giving the company a market cap of $142M. The stock is currently down 15.3% year-to-date, down 14.6% over the past 12 months, and down 85.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 37.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 2726.8% The company's stock price performance over the past 12 months beats the peer average by -8.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Zacks: Brokerages Expect Synlogic, Inc. (NASDAQ:SYBX) to Announce -$0.28 Earnings Per Share  2021/12/12 18:14:42 Dakota Financial News
Brokerages expect Synlogic, Inc. (NASDAQ:SYBX) to announce earnings of ($0.28) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Synlogics earnings, with the lowest EPS estimate coming in at ($0.33) and the highest estimate coming in at ($0.24). Synlogic reported earnings of ($0.39) per share in the same quarter []
   Synlogic (NASDAQ:SYBX) Rating Lowered to Hold at Zacks Investment Research  2021/12/10 09:14:42 Dakota Financial News
Synlogic (NASDAQ:SYBX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The companys []
   Synlogic appoints Michael Jensen as CFO  2022/03/03 12:36:58 Seeking Alpha
Synlogic (SYBX) has appointed Michael Jensen as CFO. Mr
   Synlogic Inc Shares Fall 0.5% Below Previous 52-Week Low - Market Mover  2022/01/14 01:12:46 Kwhen Finance
Synlogic Inc (SYBX) shares closed 0.5% lower than its previous 52 week low, giving the company a market cap of $142M. The stock is currently down 15.3% year-to-date, down 14.6% over the past 12 months, and down 85.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 37.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 2726.8% The company's stock price performance over the past 12 months beats the peer average by -8.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Zacks: Brokerages Expect Synlogic, Inc. (NASDAQ:SYBX) to Announce -$0.28 Earnings Per Share  2021/12/12 18:14:42 Dakota Financial News
Brokerages expect Synlogic, Inc. (NASDAQ:SYBX) to announce earnings of ($0.28) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Synlogics earnings, with the lowest EPS estimate coming in at ($0.33) and the highest estimate coming in at ($0.24). Synlogic reported earnings of ($0.39) per share in the same quarter []
   Synlogic (NASDAQ:SYBX) Rating Lowered to Hold at Zacks Investment Research  2021/12/10 09:14:42 Dakota Financial News
Synlogic (NASDAQ:SYBX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The companys []
   Phenylketonuria Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight  2021/12/08 01:00:00 Benzinga
Los Angeles, USA, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Phenylketonuria Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight There are approximately 15+ key companies developing the Phenylketonuria therapies. In the upcoming years, many new products such as CNSA-001/PTC923 (PTC Therapeutics), HMI-102 (Homology Medicines), and SYNB1618 (Synlogic) are also expected to enter the Phenylketonuria market. PTC-923 is expected to be the most promising drug among all the upcoming therapies. DelveInsight''s " Phenylketonuria Pipeline Insight " report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Phenylketonuria pipeline landscapes. It comprises Phenylketonuria pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Phenylketonuria therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Phenylketonuria pipeline products. Some of the key takeaways from the Phenylketonuria Pipeline Report Major companies such as Synlogic, Homology Medicines, PTC therapeutics, Rubius Therapeutics, NestlÃ, BioMarin, SOM Biotech, Evox Therapeutics, Moderna Therapeutics, Orpharma, Generation Bio, Erydel, Janana therapeutics, American gene technologies, Applied Pharma Research and others are developing potential drug candidates to improve the Phenylketonuria treatment scenario.
   Mesmerizing stocks: Teligent, Inc. (NASDAQ:TLGT -8.02%), Synlogic, Inc. (NASDAQ:SYBX -2.62%)  2021/10/02 00:47:24 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Mesmerizing stocks: Teligent, Inc. (NASDAQ:TLGT -8.02%), Synlogic, Inc. (NASDAQ:SYBX -2.62%) appeared first on Stocks Equity .
   Key Benefits Of: Synlogic, Inc. (NASDAQ:SYBX -11.32%), Comstock Mining Inc. (AMEX:LODE -2.82%)  2021/09/23 23:49:40 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Key Benefits Of: Synlogic, Inc. (NASDAQ:SYBX -11.32%), Comstock Mining Inc. (AMEX:LODE -2.82%) appeared first on Stocks Equity .
   Bewitching stocks: Surgalign Holdings, Inc. (NASDAQ:SRGA -0.75%), Synlogic, Inc. (NASDAQ:SYBX -2.42%)  2021/09/22 22:57:02 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Bewitching stocks: Surgalign Holdings, Inc. (NASDAQ:SRGA -0.75%), Synlogic, Inc. (NASDAQ:SYBX -2.42%) appeared first on Stocks Equity .
   Synlogic launches common stock offering  2021/09/22 20:08:11 Seeking Alpha
   Why Are Synlogic Shares Moving Higher Premarket Monday?  2021/09/20 12:31:22 Benzinga
Synlogic Inc (NASDAQ: SYBX ) has announced data from clinical studies evaluating SYNB1618 and SYNB1934 for phenylketonuria (PKU). PKU is a rare genetic disease that manifests at birth and is characterized by an inability to break down phenylalanine, an amino acid commonly found in many foods. Interim analysis of Phase 2 SynPheny-1 study trial of SYNB1618 demonstrated clinically meaningful reductions of Full story available on Benzinga.com

 関連キーワード  (医薬品 米国株 マイア―ルエヌエイ・セラピュ―ティクス SYBX Synlogic Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)